Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser

Blue Laser (488 nm)

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, et al. 2005. Immunology 116:487.
5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed

Product Citations

1. Guo X, et al. 2016. Mol Ther Methods Clin Dev. 3:15054. PubMed
2. Zitti B, et al. 2017. Sci Rep. 10.1038/s41598-017-10403-0. PubMed
3. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
4. Want MY, et al. 2019. Oncoimmunology. 8:e1586042. PubMed
5. Lugo-Reyes SO, et al. 2021. J Clin Immunol. 41:1291. PubMed
6. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
7. Clayton K, et al. 2014. J Immunol. 192:782. PubMed
8. Shi Z, et al. 2021. Ann Clin Transl Neurol. 8:43. PubMed
9. Catapano M, et al. 2020. J Invest Dermatol. 140:816. PubMed
10. Wang Y, et al. 2019. J Transl Med. 17:93. PubMed
11. Wu X, et al. 2020. Cancers (Basel). 12:. PubMed
12. Moen IN, et al. 2021. Cell Death Discov. 7:36. PubMed
13. Dai Q, et al. 2020. Front Immunol. 11:539654. PubMed
14. Yamada E, et al. 2021. Gut Microbes. 13:1997292. PubMed
15. Zhang B, et al. 2022. J Exp Med. 219:. PubMed
16. Lin L, et al. 2018. Oncol Lett. 16:1259. PubMed
17. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
18. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
19. Celik H, et al. 2021. Cancer Discov. 11:3126. PubMed
20. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
21. Giesecke C, et al. 2017. Cytometry A. 10.1002/cyto.a.23250. PubMed
22. Gillissen MA, et al. 2018. Blood. 131:131. PubMed
23. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
24. Kim K, et al. 2019. Nat Microbiol. 1.586111111. PubMed
25. Sperk M, et al. 2021. iScience. 24:102111. PubMed
26. Nakasone H, et al. 2021. Commun Biol. 4:1177. PubMed
27. Wu X, et al. 2021. Front Immunol. 12:731767. PubMed
28. Jeyanathan M, et al. 2022. JCI Insight. 7:. PubMed
29. Omer OS, et al. 2020. Methods Mol Biol. 2121:199. PubMed
30. Hazenberg MD, et al. 2019. Blood Adv. 2.659722222. PubMed
31. Golebski K, et al. 2021. Immunity. 54(2):291-307.e7. PubMed
32. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
33. Agashe VV, et al. 2018. J Immunol. 201:772. PubMed
34. Oyer JL, et al. 2022. Front Immunol. 13:861681. PubMed
35. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
36. Aagaard K, et al. 2017. Sci Rep. 7:41389. PubMed
37. Miyamae Y, et al. 2020. Cell Chemical Biology. 27(12):1573-1581.e3. PubMed
38. Cheng J, et al. 2022. iScience. 25:103588. PubMed
39. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
40. Zhang W, et al. 2022. J Transl Med. 20:558. PubMed
41. Zhao B, et al. 2013. PLoS One. 8:77708. PubMed
42. Bal S, et al. 2016. Nat Immunol. 10.1038/ni.3444. PubMed
43. Winkler C, et al. 2021. JCI Insight. 6:. PubMed
44. Akusj?rvi SS, et al. 2022. iScience. 25:103607. PubMed
45. Zhou Z, et al. 2022. J Gastrointest Oncol. 13:732. PubMed
46. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
47. Shikhagaie M, et al. 2017. Cell Rep. 18(7):1761-1773. PubMed
48. Gopalakrishnapillai A, et al. 2021. Cancers (Basel). 13:. PubMed
49. Fierle JK, et al. 2021. Cell Reports Medicine. 2(8):100362. PubMed
50. Sullivan KD et al. 2016. eLife. 5 pii: e16220. PubMed
51. Ochi T, et al. 2011. Blood. 118:1495. PubMed
52. Svensson Akusj?rvi S, et al. 2022. Commun Biol. 5:357. PubMed

RRID

AB_571906 (BioLegend Cat. No. 317305) AB_571907 (BioLegend Cat. No. 317306)